REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies

REGENXBIO Inc. announced on May 15th its plan to construct a current good manufacturing practice (cGMP) production facility, to be located in Rockville, Maryland. The new cGMP production facility will be integrated into REGENXBIO’s previously announced new 132,000 square foot headquarters, for which construction is currently underway, and will allow for production of NAV Technology-based vectors at scales up to 2,000 liters using REGENXBIO’s platform suspension cell culture process.  The facility will be designed to meet global regulatory requirements and is expected to be operational in 2021. The cGMP production facility will complement the company’s current external manufacturing capabilities, enabling a reliable supply of NAV vectors from both internal and external sources. The construction of the facility is not expected to have any effect on REGENXBIO’s previously issued financial guidance relating to its cash, cash equivalents and marketable securities as of December 31, 2019

For further information see ReGenXbio (http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-launch-new-manufacturing-facility-nav-technology-based)